טוען...
Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year
BACKGROUND: Bone mineral density (BMD) declines when zoledronic acid (ZA) is administered. This case series describes the patterns of change in BMD when 1 or 2 doses of ZA are administered after denosumab. METHODS: Twelve patients who received at least 2 doses of denosumab followed by at least 1 dos...
שמור ב:
| הוצא לאור ב: | J Bone Metab |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Society for Bone and Mineral Research
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7973401/ https://ncbi.nlm.nih.gov/pubmed/33730783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.11005/jbm.2021.28.1.51 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|